



**FOR IMMEDIATE RELEASE**

**Media Contact:**

Pure Communications, Inc.  
Dan Budwick, (973) 271-6085  
dan@purecommunicationsinc.com

**Ablexis Appoints Jake Bauer as Senior Director, Corporate Development  
and Business Operations**

**San Francisco – June 15, 2011** – [Ablexis](#), LLC, a biotechnology company dedicated to developing the AlivaMab Mouse, an innovative platform for discovery of the next generation of breakthrough antibody drugs, announced today the appointment of Jake Bauer as senior director, corporate development and business operations. Reporting to Larry L. Green, Ph.D., chief executive officer of Ablexis, Mr. Bauer will lead development and implementation of the next phase of the company's corporate strategy and oversee business operations.

"We are very excited to welcome Jake as a full-time member of the Ablexis team," said Dr. Green. "In his role as a leader of Third Rock Ventures' investment in Ablexis, and then as an observer on the Ablexis board of directors, Jake has already made significant contributions to the company, demonstrating both strategic and tactical insight. We expect his experiences and capabilities in building companies will be extremely valuable as we continue leveraging the potential of our AlivaMab Mouse antibody discovery platform beyond the five-member Ablexis-Pharma Consortium we established in 2010."

Mr. Bauer has a decade of experience in corporate development, business development, entrepreneurship and business operations. As a principal at Third Rock Ventures, he identified, evaluated and developed new opportunities for investment, negotiated financings and assisted with start-up, corporate development and operations of portfolio companies. He was also actively involved in a variety of leading biopharmaceutical companies including Ablexis, Agios, CytomX and Zafgen. Prior to joining Third Rock Ventures, Mr. Bauer served in roles in the investment group at Royalty Pharma, the business development group at Endo Pharmaceuticals and was previously a management consultant at Putnam Associates. He received an M.B.A. from Harvard Business School, and a B.Sc. in Biology and a B.A. in Economics from Duke University.

**About Ablexis, LLC**

Ablexis, LLC, was founded in December 2009 based on technology established by Aliva Biopharmaceuticals, Inc. Ablexis is developing the AlivaMab Mouse, an innovative, next-generation transgenic mouse platform intended to provide the foundation for the efficient discovery and development of the next wave of human therapeutic antibodies. In October 2010, Ablexis formed a five-member consortium made up of five of the top fifteen global

pharmaceutical companies, granting each member non-exclusive licenses to the Ablexis AlivaMab Mouse technology. The company is based in San Francisco; more information can be found by visiting the company's website at [www.ablexis.com](http://www.ablexis.com).

###